DavidPerlmutterMD · 2022-03-28 · David Perlmutter (host), Max Lugavere

What to Eat for Optimal Brain Health - with Max Lugavere | The Empowering Neurologist EP. 147

48 research-tied claims examined: 2 contradicted 5 overstated 5 context 33 supported 3 unverified

5

Overstated

0:13:40David Perlmutter (host)overstatedhigh

An individual who reaches the age of 85 has a 50% chance of developing Alzheimer's disease.

"if you live to be age 85, it's going to be 50/50 anyway." (said at 0:13:40)

The claim that reaching age 85 carries a 50% chance (or 50/50 odds) of developing Alzheimer's disease substantially overstates epidemiological estimates. According to large-scale epidemiological data and annual reports from the Alzheimer's Association, approximately one-third (about 32% to 34%) of individuals aged 85 and older have Alzheimer's dementia, not half. Furthermore, the remaining lifetime risk of developing Alzheimer's disease at or after age 85 is estimated to be well below 50% (roughly 10% to 15% for men and 15% to 20% for women, depending on mortality and risk factors). While age remains the strongest known risk factor for Alzheimer's dementia, reaching 85 does not confer a 50/50 probability.

0:28:35David Perlmutter (host)overstatedmoderate

Fructose consumption inhibits leptin signaling and stimulates appetite.

"the most powerful food that we would consume that would tell us to keep eating, that inhibits leptin, that makes us want to eat more, is fructose." (said at 0:28:35)

While dietary fructose ingestion results in lower acute postprandial insulin and leptin secretion compared with glucose, and chronic high-fructose diets have been linked to leptin resistance and increased energy intake in animal and human studies, characterizing fructose as the 'most powerful' food that inhibits leptin and stimulates appetite is an overstatement. Multiple dietary factors, particularly overall positive energy balance, high saturated fat, and mixed high-sugar diets, contribute substantially to impaired leptin signaling and reduced satiety.

0:36:27David Perlmutter (host)overstatedvery low

Elevated serum sodium following a high-salt meal triggers the body to produce endogenous fructose, signaling fat synthesis via uric acid.

"We know that when the sodium goes up, as in after a very highly salted meal, it triggers the body to produce its own fructose, and that is a signal to make fat through uric acid." (said at 0:36:27)

The proposed pathway—where high sodium/osmolarity upregulates aldose reductase to drive endogenous fructose synthesis via the polyol pathway, which in turn leads to fructokinase-mediated uric acid generation and downstream lipogenesis—is supported by preclinical rodent and in vitro studies. However, presenting this as an established physiological consequence of a single high-salt meal in humans overstates the evidence, which currently relies almost entirely on animal models, cell cultures, and observational associations.

0:42:22David Perlmutter (host)overstatedmoderate

A meta-analysis published in a JAMA journal by Dr. Richard Kennedy found that Alzheimer's patients taking cholinesterase inhibitor drugs experienced more rapid cognitive decline compared to matched non-users.

"A Dr. Richard Kennedy publishing in the journal JAMA, Journal of the American Medical Association network journal, published a meta-analysis, I think 12 studies, several thousand people, and he demonstrated quite convincingly that those individuals who do take that drug actually have more rapid cognitive decline in comparison to matched individuals who do not take the so-called magic Alzheimer's pill." (said at 0:42:22)

Dr. Richard E. Kennedy and colleagues published a meta-analysis in JAMA Network Open (2018) analyzing 10 Alzheimer disease clinical trial cohorts (2,714 participants) examining concomitant medication use. They found that participants taking cholinesterase inhibitors (ChEIs) or memantine exhibited a greater annual rate of cognitive decline on the ADAS-cog (1.4 points/year; 95% CI, 0.1-2.7) compared to those taking neither. However, the speaker overstates the causal and methodological nature of the findings: this was an observational analysis within clinical trials, not a matched causal trial demonstrating that the medication itself accelerates decline. The authors explicitly cautioned that this association is likely subject to confounding (such as confounding by indication, where patients with faster-progressing or more severe disease are more likely to be prescribed medication).

0:51:18David Perlmutter (host)overstatedmoderate

Having type 2 diabetes may quadruple a person's risk for developing Alzheimer's disease.

"If you're type 2 diabetic, you may have quadrupled your risk for Alzheimer's." (said at 0:51:18)

Large meta-analyses confirm that diabetes is associated with an increased risk of developing Alzheimer's disease, but the relative risk is substantially lower than a fourfold (quadrupled) increase. A systematic review and meta-analysis involving over 3.3 million participants found that diabetes was associated with approximately a 36% increase in Alzheimer's risk (hazard ratio 1.36, 95% CI: 1.19–1.55), with subgroup estimates ranging between 1.29 and 1.45. While type 2 diabetes is a recognized independent risk factor for cognitive decline, asserting that it quadruples Alzheimer's risk significantly overstates the evidence.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.